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Abstract 
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease that affects 
motor neurons of the brain and spinal cord. Many studies indicate that mitochondrial 
oxidative stress (MOS) is a principal mechanism underlying the pathophysiology of this 
and other devastating neurodegenerative diseases. Here, we investigated a unique whey 
protein supplement (Immunocal®) to determine its neuroprotective efficacy in several in 
vitro models of MOS and in an in vivo mouse model of ALS. This non-denatured whey 
supplement contains cystine which is an oxidized form of cysteine, an essential precursor 
for synthesis of the endogenous antioxidant, glutathione (GSH). In primary cultured rat 
cerebellar granule neurons (CGNs), pre-incubation with Immunocal® completely 
protected against MOS induced by HA14-1, an inhibitor of the pro-survival Bcl-2 
protein. This effect was prevented by co-incubation with the gamma-glutamyl cysteine 
ligase inhibitor, buthionine sulfoximine, demonstrating that the de  novo synthesis of 
GSH underlies the neuroprotective mechanism of Immunocal®. Additionally, 
Immunocal® displayed significant protection against an array of MOS-inducing agents, 
including sodium nitroprusside, copper, and aluminum, supporting its ability to 
upregulate mitochondrial antioxidant capacity. In accordance with these findings in 
CGNs, Immunocal® decreased cell death due to both H2O2 and glutamate toxicity in 
NSC34 motor neuron-like cells. Immunocal® also significantly protected CHO cells 
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from MOS evoked by overexpression of amyloid precursor protein (APP). Immunocal® 
treatment in NSC34 motor neuron-like cells decreased cell death caused by both H2O2 
and glutamate glycine. Most compelling are our findings in the hSOD1
G93A
 mouse model 
of ALS. These mice were given Immunocal® (3.33% solution in drinking water) ad 
libitum, beginning at 60-days-old. Although no effect on overall survival was observed, 
Immunocal®-treated mice displayed a significant (7 ±1.08 day) delay in disease onset, 
compared to mutant control mice. Importantly, Immunocal®-treated mice showed a 
highly significant decrease in the rate of decline in grip strength. Finally, using HPLC-
ECD we found that whole blood and lumbar spinal cord GSH levels were each depleted 
by nearly 50% in end-stage hSOD1
G93A
 mice, and these reductions were essentially 
prevented in mutant mice receiving Immunocal®. These findings suggest that sustaining 
GSH by supplementation with Immunocal® may help to mitigate the progression of ALS 
through suppression of MOS. In addition to investigating Immunocal® for its 
neuroprotective efficacy, we also show that an anthocyanin-enriched fraction from 
strawberries delays disease onset and extends survival in the hSOD1
G93A
 mouse model of 
ALS. These cumulative data suggest that nutraceutical antioxidants hold promise in 
neurodegenerative disease.  
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Chapter 1: Introduction 
1.1.  Oxidative stress and neurodegenerative disease 
Mitochondrial oxidative stress (MOS) and dysfunction are major factors 
underlying the pathophysiology of several devastating neurodegenerative disorders 
including Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic 
lateral sclerosis (ALS) [1]. Reactive oxygen species (ROS) are generated in 
substantial quantities during normal cell metabolism, in particular, at the level of 
mitochondria as a byproduct of electron transport and ATP production. ROS can play 
essential roles in cell signaling; however, when these free radicals are produced in 
excess of antioxidant defense mechanisms, cell damage and death will follow [2,3]. 
The brain is especially vulnerable to oxidative damage because of its high lipid 
content and high rate of oxygen consumption. As a result of oxidative damage, 
region-specific neuronal cell death is an underlying cause of each of the above-
mentioned neurodegenerative diseases [4]. 
There is mounting evidence suggesting that deficiencies in the electron transport 
chain (ETC) and subsequent oxidative stress at the level of the mitochondria are 
integral factors in a variety of neurodegenerative diseases [5,6]. ETC deficits lead to 
decreased ATP production and increases in ROS [7]. More specifically, oxidative 
damage causes complex I deficiencies in the ETC and further increases ROS 
2 
 
production in PD [8]. For instance, complex I deficiency and the consequent increase 
in mitochondrial ROS play a critical role in the death of dopaminergic neurons in PD 
[9]. Consistent with this concept, mice heterozygous for deletion of the 
mitochondrial-specific, manganese-superoxide dismutase (SOD2) gene show 
markedly increased susceptibility to dopaminergic neuronal loss induced by the 
complex I inhibitor, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine [10]. 
Pathophysiologically relevant complex I inhibitors such as rotenone and N-
methylpyridinium ion (MPP
+
) generate free radicals and induce dopaminergic 
pathology which is used to model PD in vitro and in vivo for studies into potential 
therapeutics [11,12].  Methods aimed at bolstering endogenous antioxidant defense 
mechanisms to scavenge free radicals generated by these toxic compounds during 
disease progression hold therapeutic potential for neurodegenerative diseases such as 
PD.  
Additionally, amyloid-β precursor protein (AβPP) aggregates, which are a 
pathological hallmark in AD, have been shown to induce MOS and cytochrome c 
release in vitro and in vivo [13,14]. Aβ accumulation and oligomerization has been 
proposed to lead to mitochondrial dysfunction and caspase activation [15]. In either 
patients with AD or mutant AβPP transgenic mice, beta-amyloid associates with the 
mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) and triggers an enhanced 
generation of mitochondrial ROS [16]. Moreover, overexpression of ABAD in mutant 
AβPP expressing mice increases neuronal oxidative stress and worsens spatial 
memory deficits. Conversely, crossing of Tg19959 mutant AβPP transgenic mice 
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with mice overexpressing SOD2 significantly reduces amyloid plaque burden and 
sustains spatial memory relative to Tg19959 control mice [17]. Healthy and 
functional mitochondria are imperative for defense against Aβ-induced oxidative 
stress; therefore, therapies that enhance intrinsic antioxidant activity have promise for 
this particular neurodegenerative disease [18]. More specifically, strategies that 
protect cells at the level of the mitochondria appear to have protective potential in 
these diseases [19]. 
1.2. GSH is a key endogenous antioxidant 
One of the crucial modulators of cell survival, under both normal and pathological 
conditions, is the endogenous tri-peptide glutathione (GSH, γ-glutamyl-L-cysteinyl-
glycine). GSH is involved in many essential cell processes including DNA synthesis 
and cell metabolism, but its primary function is to act as an antioxidant and scavenger 
of ROS [20]. GSH exists in a reduced and active state and is oxidized to glutathione 
disulfide (GSSG) upon reducing unstable molecules, such as ROS. The reduction of 
ROS by GSH is facilitated by the enzyme GSH peroxidase (GPx) [21]. The enzyme, 
glutathione reductase (GR), then returns GSSG to its reduced form GSH (Fig. 1) [22]. 
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Figure 1. Glutathione metabolism. 
  
Biosynthesis of GSH happens in two distinct steps. The first occurs when γ-
glutamylcysteine ligase (GCL) combines glutamate and cysteine together. This 
reaction is the rate-limiting step in GSH synthesis. The second step in GSH synthesis 
occurs when GSH synthetase adds glycine to the C-terminus of the end product of the 
first step, γ-glutamylcysteine. Cysteine is the rate-limiting precursor in GSH synthesis 
(Fig. 2) [22-24]. Because of its potent antioxidant activity, and its neuroprotective 
capacity demonstrated in many in vitro and in vivo systems (discussed below), 
strategies that enhance GSH synthesis have drawn attention as potentially novel 
therapies for neurodegenerative diseases [reviewed in 25].  
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Figure 2. Glutathione synthesis. 
  
1.3. Neuroprotective effects of GSH and GSH precursors in vitro and in vivo 
Several strategies to increase levels of endogenous GSH have previously shown 
to be effective in disease treatment in vitro and in vivo. N-acetylcysteine (NAC) 
supplementation provides cysteine in a cell-permeable and non-toxic form, and has 
been studied for its efficacy in various neurodegenerative and progressive human 
diseases [26-28]. NAC supplementation decreased ROS levels and increased cell 
antioxidant potential against rotenone-induced apoptosis in vitro and in a rat model of 
PD in vivo. Cell survival was significantly increased in NAC-treated cells and 
animals in these models of PD, suggesting that NAC reduced toxicity with its ability 
to decrease oxidation of cellular GSH and subsequently decrease ROS [29]. NAC 
treatment in SHSY5Y cells has also been shown to decrease levels of Aβ 1-42, and to 
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decrease the levels of phospho-tau protein, which are hallmarks in AD [30]. Finally, 
NAC has been investigated in a model of ALS, where it delayed clinical onset and 
prolonged survival in hSOD1
G93A
 mice, a familial model of ALS [31]. 
In addition to NAC, other means of increasing GSH levels have been investigated 
for prevention and treatment of various neurodegenerative diseases, though the 
research is not as comprehensive as with NAC. Glutathione monoethylester (GSH-
MEE) is a cell permeable derivative of GSH. Its efficacy has been investigated in 
several murine models of neurodegeneration. GSH-MEE has been shown to prevent 
mitochondrial GSH depletion and to provide neuroprotection following transient 
focal cerebral ischemia [32,33]. Additionally, GSH-MEE has been shown to improve 
recovery and survival of spinal cord neurons in a model of spinal cord injury in rats 
[34]. These approaches, among other methods of increasing intracellular GSH, are 
unique and deserve further investigation in the lab and in the clinic.  
1.4. GSH depletion plays a central role in ALS pathogenesis 
ALS is the most common adult-onset motor neuron disease. It is characterized 
clinically by progressive muscle weakness and atrophy, ultimately leading to 
respiratory failure and death, typically within 1 to 5 years of diagnosis. There is 
currently only one FDA approved drug for ALS, riluzole, which is an anti-
glutamatergic compound that merely prolongs survival by 2 to 3 months and has little 
effect on quality of life for ALS patients [35,36]. ALS is characterized pathologically 
by a progressive loss of motor neurons in the cortex, brainstem, and spinal cord [37]. 
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Though its underlying cause remains elusive, oxidative damage due to aberrant 
production of ROS and associated mitochondrial dysfunction play key roles in motor 
neuron death [38,39,40].  
In the case of ALS, mutant forms of copper, zinc-superoxide dismutase (SOD1) 
which are collectively responsible for approximately 20% of cases of familial ALS, 
accumulate at mitochondria and trigger a shift in the redox state of these organelles 
[41]. G93A mutant SOD1 displays a gain-of-toxic-function which is characterized by 
an increased generation of mitochondrial ROS [42]. Finally, crossing of hSOD1
G93A
 
mutant mice with mice heterozygous for deletion of the SOD2 gene significantly 
exacerbates motor neuron pathology and reduces lifespan in this model of familial 
ALS, indicating a central role of MOS in disease pathogenesis [43]. 
Given the key role of MOS in neuronal cell death, identifying the major players 
that regulate the mitochondrial oxidant/antioxidant balance is essential to discover 
novel therapeutics for neurodegeneration. Glutathione (GSH) is an endogenous 
tripeptide antioxidant that plays a central role in preventing MOS and evading 
apoptosis [44]. GSH depletion and a decline in antioxidant enzyme activity have been 
observed in the erythrocytes of sporadic ALS patients with active disease [45]. This 
decrease in antioxidant defense enzyme activity and GSH metabolism has been 
correlated directly with the rate of disease progression [46]. Many characteristic 
pathological changes observed in ALS may be induced by intracellular GSH 
depletion. For example, the protein TAR DNA-binding protein 43 (TDP-43) forms 
cytoplasmic inclusions, which is one of the hallmark pathologies seen in sporadic 
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ALS patients. These TDP-43 inclusions can be recapitulated in cultured neurons 
subjected to GSH depletion [47]. Oxidative stress also causes accumulation and 
aggregation of mutant SOD1 in familial ALS, and these inclusions have been shown 
to decrease GSH content, which is attributed to disruption of mitochondrial function 
[48,49]. In agreement, SOD1 knockout causes oxidative stress and subsequent distal 
motor axonopathy, as well as significant GSH oxidation [50].  
The familial ALS-associated mutant, hSOD1
G93A
, has recently been shown to 
have significant effects on mitochondrial GSH in vitro. NSC34 motor neuronal cells 
stably expressing hSOD1
G93A
 display a significant and selective decrease in 
mitochondrial GSH content when compared to parental NSC34 cells [51]. 
Furthermore, these NSC34/hSOD1
G93A
 cells demonstrate significantly enhanced 
sensitivity to the GSH depleting agent, ethacrynic acid. In a similar manner, infection 
of NSC34 cells with adenoviral hSOD1
G93A
 induces oxidative stress, mitochondrial 
dysfunction, and intrinsic apoptosis which are significantly alleviated by co-
expression of the mitochondrial antioxidant enzymes SOD2 and GSH peroxidase-4 
[52]. Finally, NSC34 cells expressing hSOD1
G93A
 but not wild type SOD1, show 
marked morphological and functional alterations in mitochondria and exhibit a 
significant decrease in the reduced GSH to oxidized GSSG ratio in mitochondria 
following exposure to the inflammatory cytokines, tumor necrosis factor alpha and 
interferon gamma [53]. Thus, hSOD1
G93A
 appears to sensitize motor neuronal cells to 
MOS and apoptosis by specifically diminishing the mitochondrial GSH pool. These 
cumulative data suggest a prominent role for GSH depletion in ALS pathogenesis and 
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therefore, there is great interest in developing a method to target this aspect of the 
disease for ALS, other neurodegenerative diseases, as well as non-neuronal 
progressive human diseases such as heart disease and cancer. 
 
1.5.  Nutraceutical modulation of GSH: Pre-clinical and clinical studies with 
Immunocal® 
Immunocal® is a novel undenatured whey protein supplement designed to 
augment the available intracellular GSH pool. Cellular GSH concentrations are highly 
dependent on the availability of cysteine, which is the limiting precursor in GSH 
synthesis [54,21]. The cysteine precursor, cystine, occurs in high levels in 
Immunocal® because the supplement is rich in serum albumin, alpha-lactalbumin, 
and lactoferrin. These proteins have a significant number of cystine residues in this 
undenatured preparation. In addition, the direct GSH precursor, glutamylcysteine, is 
also present in the serum albumin fraction of the supplement. When cystine is 
provided in this peptide form, it is readily cleaved and reduced to two cysteine 
molecules within the target cell. This is significant, as cysteine supplementation alone 
is cytotoxic [55]. Immunocal® was initially developed as a nutritional supplement to 
increase immune system function after dietary amino acids were discovered to 
increase immune reactivity [56]. It has been investigated in several human diseases, 
and it is one of only a handful of nutritional supplements that are included in the 
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Physician’s Desk Reference (PDR). Immunocal® is comprised of natural food 
protein and is in the FDA category of generally recognized as safe (GRAS) [57]. 
Immunocal® was initially studied in various animal models or clinical disorders 
of immune system deficiency and cancer as an approach to increase the available 
GSH pool and increase cellular antioxidant and immune system defenses. Free radical 
generation is a key element of carcinogenesis and diets rich in antioxidants are 
believed to decrease one’s susceptibility to cancer [58,59]. Consistent with this, 
dietary whey protein decreased tumor burden in a mouse model of 
dimethylhydrazine-induced colon cancer [60]. Similarly, Immunocal® was shown to 
increase apoptosis in an in vitro model of human hepatoma cells by increasing 
cytotoxicity of specific chemotherapeutic agents such as baicalein, a flavone used for 
its anti-inflammatory and anti-proliferative properties in cancer cells [61]. In addition 
to its anti-tumor effects, this undenatured whey protein was shown to reverse weight 
loss in lung cancer patients receiving chemotherapy or radiotherapy [62]. Thus, 
Immunocal® provides anti-cancer activity while also preserving overall health, and 
its method of action may be applicable in many other human pathologies. 
Immunocal® was also investigated as a potential antioxidant therapy in human 
immunodeficiency virus (HIV) infection [63]. Oxidative stress is a known activator of 
HIV replication and based on this, Immunocal® was tested as an approach to 
attenuate this stress by increasing intracellular GSH levels. In a small pilot study, 
Immunocal® administration over 3 months was shown to elevate blood GSH by 70% 
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in HIV-seropositive individuals back to normal values [64]. Moreover, this restorative 
effect on blood GSH was associated with parallel increases in bodyweight.  
Oxidative stress plays a significant role in muscle weakness. Immunocal® 
administration for 3 months was shown to significantly increase muscle power and 
work capacity in comparison to individuals that received placebo treatment. 
Undenatured whey protein supplementation also significantly increased lymphocyte 
GSH levels compared to placebo (36% +/- 11%) [65]. Oxidative stress is also key in 
the pathogenesis of cystic fibrosis. It is well accepted that GSH is a major defense in 
lung diseases, such as cystic fibrosis, and treatment methods that augment the 
available pool of this antioxidant are continually investigated. In cystic fibrosis 
patients receiving Immunocal® for 3 months, there was a 46.6% increase in 
lymphocyte GSH levels compared to individuals receiving a placebo [66]. 
This dietary whey protein supplement was also investigated in diseases of aging, 
where it extended longevity by 6.3 months in mice that received the supplement late 
in life (specifically, over a 3 month period between 17 and 20 months of age). This 
lifespan extension in the mouse corresponds to approximately 25 human years. 
Although there was little investigation into the specific mechanism behind this effect, 
both heart and liver GSH levels were significantly increased in Immunocal®-fed mice 
[67]. To date, there has been minimal investigation into the efficacy of Immunocal® 
treatment in neurodegenerative diseases; however, with the wide array of human 
diseases that show promising results with this dietary supplement, it is encouraging 
for other progressive human diseases. Immunocal® holds potential to increase GSH 
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levels in many relevant disorders like neurodegeneration whose underlying pathology 
includes oxidative stress. 
1.6.  Immunocal® patents 
Immunocal® has not been patented specifically for use in neurodegenerative 
diseases; however, it has been investigated in depth for several other human 
pathologies. Immunocal® appears to show beneficial effects in these diseases because 
of its capacity to act as a cysteine-donor, resulting in an increase of GSH levels in 
treated individuals. Initial studies with this undenatured whey protein isolate were 
conducted to investigate its efficacy in immune system deficiency. Immunocal® is 
highly effective in bolstering immune function, and was patented because of its 
ability to improve active systemic humoral immune response [68]. More recently, it 
was patented for use in HIV-seropositive individuals, in which it induces a decrease 
in viral load and an increase in immune function in affected individuals [69]. Finally, 
Immunocal® was patented as an anti-cancer therapy because of its ability to increase 
the efficacy of certain chemotherapy agents, to decrease the oxidative stress 
component of cancer, and to increase the body weight of patients who were receiving 
chemotherapy back to healthy levels [70]. This dietary supplement provides a unique 
approach to increase intracellular GSH levels, and there is much promise for 
Immunocal® in the treatment and prevention of neurodegenerative diseases. 
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1.7.  Therapeutic approaches to modulate GSH in neurodegenerative disease 
Based on extensive evidence that oxidative stress is a fundamental aspect of 
neurodegeneration, multiple strategies have been proposed to limit free radical 
damage to the nervous system. In particular, methods designed to augment 
intracellular GSH levels are of great interest, due to the evolving pool of literature 
indicating a key role of GSH depletion in neurodegenerative disease [reviewed in 71]. 
GSH does not penetrate the blood brain barrier (BBB) and therefore, therapies aimed 
at indirectly modulating GSH levels have been investigated, including the 
introduction of GSH precursors, analogs, and mimetics [72,73]. Other strategies, such 
as bolstering the expression of enzymes responsible for increases in GSH synthesis 
for example, are also gaining interest. 
The NF-E2-related factor 2 (Nrf2) transcription factor regulates the expression of 
several prominent antioxidant defense proteins. Cellular GSH levels are dependent 
upon Nrf2 translocation into the nucleus to initiate the expression of key GSH 
synthesis enzymes including the catalytic and regulatory subunits of γ-glutamyl 
cysteine synthase (GCS) [74,75]. Nrf2 activation is therefore an interesting target to 
modulate GSH in an effort to decrease neuronal cell death in relevant 
neurodegenerative diseases. Several compounds that stimulate Nrf2 nuclear 
translocation and the subsequent increases in GSH synthesis have been investigated 
and have proven to be neuroprotective in vitro [76,77]. Consistent with these in vitro 
studies, Nrf2 overexpression in glial cells and subsequent GSH secretion from 
astrocytes increased survival and delayed disease onset in a famial mouse model of 
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ALS [78]. In a similar manner, stimulation of Nrf2-dependent GSH synthesis by 
synthetic triterpenoid compounds also delayed disease onset and enhanced survival in 
the SOD1
G93A
 mouse model of ALS [79]. These studies suggest that a promising 
approach to Nrf2 activation is increasing GSH levels in the nervous system.  
Glutamate transporter-associated protein 3-18 (GTRAP3-18) interacts with 
excitatory amino acid carrier 1 (EAAC1) at the plasma membrane. EAAC1 is a 
neuronal glutamate/cysteine transporter, responsible for regulating intracellular 
cysteine levels. It is suggested that GTRAP3-18 plays a dominant negative role in 
cysteine transport when it interacts with EAAC1 [80]. Accordingly, GTRAP3-18 
deficient mice show increased intracellular GSH levels, and these mice have 
demonstrated a decreased sensitivity to oxidative stress and increased cognitive 
function [81]. Thus, inhibitors of GTRAP3-18 may be effective inducers of GSH 
accumulation in the nervous system. 
Another technique to boost cellular GSH that has received attention is direct N-
acetyl-L-cysteine (NAC) supplementation. This has been shown to increase the 
available cysteine pool and to decrease oxidative damage [82]. Wobbler mice that 
display lower motor neuron degeneration have shown reductions in 
neurodegeneration and retention of motor function when administered NAC. They 
also display increased GSH levels and increased muscle mass [83].  
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1.8.  Modulation of GSH using Immunocal® as a neuroprotective and therapeutic 
strategy for ALS 
Although the mitochondrial GSH content in particular, has not been measured in 
vivo in spinal cord of the hSOD1
G93A
 mouse, GSH depletion has been observed in the 
spinal cord of end-stage mice [84]. Moreover, crossing of hSOD1
G93A
 mice with mice 
lacking the glutamate-cysteine ligase modifier subunit significantly accelerated 
disease progression [85]. Conversely, a number of strategies that are predicted to 
increase GSH, such as supplementation with N-acetyl-L-cysteine or induction of the 
Nrf2 transcription factor, demonstrate significant benefits on disease onset, 
progression, and survival in this model of familial ALS [31,78,79]. In the current 
study, we investigated the neuroprotective effects of a undenatured whey protein 
supplement, Immunocal®, in vitro in several models of MOS and in vivo in the 
hSOD1
G93A 
mouse model of familial ALS [86].  
1.9. Anthocyanins and neurodegeneration 
Anthocyanins are a major sub-class of the extensive flavonoid family, and they 
are responsible for the distinctive red, blue, and purple pigments in many fruits and 
vegetables.  Found in widely consumed foods, including berries, purple sweet 
potatoes, red rice, and grapes, they exist in relatively high concentrations compared to 
other dietary polyphenolic compounds [87]. Anthocyanins display a number of 
potential health benefits that warrant their investigation as potential clinical 
treatments for several human disorders. Due to their anti-inflammatory and 
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antioxidant properties, these novel nutraceuticals have proven effective in both in 
vitro and in vivo models of various chronic human conditions, including 
cardiovascular disease, obesity, atherosclerosis, ophthalmologic disorders, and type II 
diabetes [88-92]. 
The polyphenolic and cationic attributes of anthocyanins and their metabolites 
activate a variety of cellular responses.  Anthocyanins consist of an aglycon 
component, or anthocyanidin, and a sugar moiety (glucose, galactose, or arabinose). 
This anthocyanin structure is more stable than its aglycon alone, specifically in acidic 
environments such as the stomach. The polyphenolic nature of anthocyanins is 
principally responsible for their strong antioxidant and free radical scavenging 
activities, and their overall metabolic benefits.  There are many known anthocyanins 
varying in the anthocyanidin skeleton and the complexity of the attached glycoside 
(Fig. 3), implicating multiple pathways for absorption [93]. 
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Figure 3. Structure of common anthocyanins. 
 
Recent bioavailability studies suggest that anthocyanins are absorbed rapidly from 
the stomach and small intestine, and they are highly metabolized resulting in very low 
to undetectable concentrations of the parent compound being observed in plasma 
within only a few hours of consumption [94,95]. The low concentrations of parent 
anthocyanins are seemingly paradoxical to the beneficial role displayed by 
anthocyanins in vivo. This issue has drawn interest to their specific mechanism of 
action, in particular which metabolites of anthocyanins produce their positive health 
effects [96,97].  
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1.9.1. Intrinsic antioxidant activity 
Anthocyanins have a robust antioxidant capacity, which appears to be highly 
effective in several models of neurodegenerative disease [98-100].  They have a high 
oxygen radical absorption capacity (ORAC) value, which is partially responsible for 
this neuroprotective effect [101-102]. More specifically, anthocyanins act as 
antioxidants because of their ability to directly scavenge free radicals and to prevent 
ROS formation in affected cells. For example, anthocyanins decrease the formation of 
ROS in in vitro models of Aβ peptide-induced toxicity, as well as in H2O2 injury 
[99,103]. Additionally, using the highly accurate method of electron spin resonance 
(ESR) spectroscopy it has been shown that anthocyanins have a high affinity to 
scavenge 1,1-diphenyl-2-picrylhydrazyl (DPPH), alkyl, and hydroxyl free radicals, 
and that this increases dose-dependently [103].  
Anthocyanins activate the antioxidant response element (ARE), which controls 
expression of a large array of endogenous antioxidant and phase II detoxification 
genes [104]. This effect appears to be via activation of the Nrf2 transcription factor 
[103]. In addition, anthocyanins have been shown to enhance the activities of free 
radical scavenging enzymes including superoxide dismutase, catalase, and glutathione 
peroxidase [105-106]. Finally, levels of the endogenous antioxidant GSH have been 
shown to increase with anthocyanin treatment, suggesting that anthocyanins exert 
their protective effects in part, via modulation of endogenous antioxidant defenses, 
and not exclusively due to their intrinsic antioxidant activity [107]. 
19 
 
1.9.2. Anti-inflammatory properties 
Induction of inflammatory gene expression and subsequent production of 
interleukins and pro-inflammatory cytokines is a common feature in 
neurodegeneration. Methods that target these inflammatory processes may be 
beneficial in limiting neuronal apoptosis associated with disease. Anthocyanins 
exhibit significant anti-inflammatory properties, as they have been shown to inhibit 
various inflammatory biomarkers, including interleukin-8 (IL-8) [101]. In addition to 
decreased IL-8 production, pomegranate anthocyanins suppress activation of nuclear 
transcription factor kappaB (NFκB), which is responsible for the expression of 
several pro-inflammatory genes. They were also shown to inhibit mitogen-activated 
protein kinases (MAPKs), c-Jun N-terminal kinase (JNK) and extracellular signal-
regulated kinase (ERK), which are responsible for the expression of a number of pro-
inflammatory cytokines [108]. Furthermore, cherry and blackberry anthocyanins act 
as potent cyclooxygenase-2 (COX-2) inhibitors; COX-2 is an important pro-
inflammatory enzyme involved in the synthesis of prostacyclin [109,110]. 
Anthocyanins have been shown to inhibit up to 95% of COX activity at high 
concentrations (250 μg/mL) [111]. These cumulative data suggest that anthocyanins 
may be useful in attenuating inflammatory processes that are associated with 
neurodegenerative disease.  
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1.9.3. Anti-apoptotic properties 
Anthocyanins modulate specific anti-apoptotic pathways to increase survival in 
neuronal cells. They have been demonstrated to regulate both caspase-dependent and 
caspase-independent cell death pathways [112]. It is mainly by acting on a variety of 
signaling proteins that they promote cell survival. Anthocyanins from purple sweet 
potato were shown to suppress JNK activity, release of cytochrome c from 
mitochondria, and cell apoptosis in D-galactose-treated mice. Additionally, it was 
demonstrated that this protective effect was dependent on phosphatidylinositol 3-
kinase (PI3K) an upstream activator of pro-survival Akt [106,113]. Anthocyanins 
have also been shown to increase the expression of pro-survival proteins such as Bcl-
2 and to decrease levels of the pro-apoptotic protein Bax, effects which play a 
significant role in prevention of 6-hydroxydopamine (6-OHDA)-induced toxicity, a 
model of PD [114]. 
1.10. Anthocyanin absorption and blood brain barrier permeability 
Intact anthocyanins taken orally are absorbed rapidly into many relevant tissues 
[115,116]. There is considerable interest into the mechanism behind this rapid 
absorption, as revealing this process could lead to further development of these 
nutraceuticals for treatment of many pertinent diseases. It is likely that absorption 
initially occurs in the stomach, which accounts for the rapid kinetics of anthocyanins 
appearing in plasma [117]. There is accumulating data suggesting that anthocyanin 
transport occurs via a bilitranslocase transporter, primarily into the vascular 
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endothelium, and subsequently into target tissue [118]. Despite their rapid uptake into 
the systemic circulation, the overall bioavilability of anthocyanins is very low due to 
their rapid metabolism and excretion principally as glucuronidated, methylated, and 
glycosylated species [119]. 
Anthocyanins are present in brain endothelial cells and in brain parenchymal 
tissue of rodents after one treatment, suggesting that they are capable of crossing the 
blood brain barrier (BBB) [120]. They are rapidly transported to the brain after 
ingestion, and once there they may accumulate to concentrations up to 0.21 nmol/g of 
tissue [121]. It is posited that anthocyanins enter the brain in a similar fashion to their 
absorption in the stomach and GI tract. There is a bilirubin-binding motif in 
bilitranslocase in the CNS, which is likely the transporter involved in transporting 
anthocyanins into the CNS [122]. This interaction occurs between the anthocyanin 
and the bilitranslocase due to hydrogen bonds and not charge, which provides further 
selectivity for this transport mechanism [123]. Although they do penetrate the BBB, 
the concentrations of parent anthocyanins detected in brain tissue after oral 
administration fall well below the concentrations which display significant 
antioxidant and neuroprotective effects in vitro. This finding suggests that metabolites 
of anthocyanins may also play significant neuroprotective roles in vivo. Moreover, 
the ability of chronic anthocyanin administration to induce accumulation of 
anthocyanins in brain has not been studied. Ultimately, there is very little known 
about anthocyanin transport, specifically for BBB permeation, or the possible 
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accumulation of anthocyanins or their metabolites in brain after chronic oral dosing. 
Both of these areas warrant further investigation. 
1.11. Anthocyanin metabolites in neurodegeneration 
There are several anthocyanin metabolites that show promise for prevention and 
treatment in neurodegenerative disease. Anthocyanin metabolites may be responsible 
for the high bioactivity of anthocyanin compounds, despite their apparently low 
bioavailability. The various identified metabolites are more stable than the whole 
anthocyanins in a variety of conditions, which make them more likely candidates as 
the bioactive moieties in target tissues [96,97]. Recent research suggests that different 
anthocyanin conjugates are found in high concentrations in circulation, including 
sulfated, methylated, glucuronidated, and glycosylated conjugates [124].  
Protocatechuic acid (PCA) and the anthocyanidin base are common anthocyanin 
metabolites (Fig. 4). During metabolism, the anthocyanidin in its aglycone form has a 
tendency to stay intact and retain its basic function. From there, conjugates of the 
anthocyanin are readily formed [125]. PCA concentrations have been detected up to 
eight times higher than the parent anthocyanin in rodent plasma. PCA has also been 
shown to remain in target tissues for longer periods of time than the parent 
anthocyanins [126]. 
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Figure 4. Common anthocyanin metabolites. 
 
Significantly, both PCA and the anthocyanidin base provided significant 
protection and decrease of ROS formation in SH-SY5Y neuronal cells treated with 
H2O2 [127]. Finally, PCA induced the Nrf2 transcription factor in murine 
macrophages; whether similar effects would be observed in neuronal or glial cells has 
not been investigated [128]. There are relatively few studies into the neuroprotective 
properties of isolated anthocyanin metabolites; however, with the pool of data 
suggesting their relevant concentrations and accumulation in tissue, it is important to 
further investigate their neuroprotective effects both in vitro and in vivo [129]. 
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1.12. Hypothesis and rationale  
Given the recent interesting research involving GSH modulation as a method to 
moderate neurodegeneration, we pursued nutraceuticals that could potentially provide 
neuroprotection by this mechanism. Nutraceutical intervention is an appealing option 
because of the relatively low side effects and high availability for patients; therefore, 
we decided to investigate the efficacy of the whey protein supplement, Immunocal®, 
which had yet to be studied in models of neurodegeneration. This protein isolate was 
interesting due to its high purity and undenatured conformation, yielding a greater 
concentration of active cystine that could be converted to cysteine, which is the 
limiting precursor in GSH synthesis. We tested its neuroprotective potential both in 
vitro, and eventually in vivo in the hSOD1
G93A
 mouse model of ALS.  
In addition to our interest in modulating the available GSH pool with 
nutraceutical intervention, we investigated natural compounds that could bolster 
cellular antioxidant response by different mechanisms. There is an increasing pool of 
literature (discussed above) that points to anthocyanins decreasing cellular apoptosis 
in disease models. This was novel, as anthocyanins have never been investigated for 
their potential in motor neuron disease. These two separate nutraceutical interventions 
had the potential to increase cellular antioxidant defenses through different 
mechanisms, and they were very appealing as new therapeutic strategies for 
neurodegenerative disease. 
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1.13. Summary of major findings 
Using in vitro and in vivo models of neurodegeneration, we show here that 
Immunocal® protected CGNs from various sources of oxidative stress. Immunocal® 
decreased cell apoptosis in CGNs treated with the Bcl-2 inhibitor, HA14-1, and this 
protective effect was diminished by the inhibitor of de novo GSH synthesis, BSO. 
Additionally, Immunocal® treatment rescued CGNs from CuCl2, AlCl3, and sodium 
nitroprusside (SNP)- induced apoptosis. Furthermore, Immunocal® decreased active 
caspase-3 expression in CHO cells that were transfected with wild type APP. 
Immunocal® also decreased cell death caused by both H2O2 and glutamate glycine in 
the motor neuron-like cell line, NSC34s. Next, we evaluated its potential benefit in 
ALS by administering it to hSOD1
G93A
 mice. Consistent with prior findings, in which 
Immunocal® protected neurons in vitro from MOS via a GSH-dependent mechanism, 
this supplement also preserved blood and spinal cord GSH levels in end-stage 
hSOD1
G93A
 mice, delayed disease onset, and sustained grip strength in this model of 
familial ALS. 
After isolating an anthocyanin-enriched extract from freeze dried strawberries 
(SAE), we tested its efficacy in the hSOD1
G93A
 mouse model of ALS. SAE 
administration delayed disease onset, increased lifespan, and sustained grip strength 
in this model of familial ALS. In summary, both Immunocal® and SAE displayed 
neuroprotective effects, likely due to their different effects on bolstering both 
exogenous and endogenous antioxidant defenses.  
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Chapter 2: Materials and Methods 
2.1. Materials 
2-amino-6-bromo-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid 
ethyl ester (HA14-1), and sodium nitroprusside (SNP) were obtained from 
Calbiochem (San Diego, CA). DL-buthionine-sulfoximine (BSO), 4,6-diamidino-2-
phenylindole (DAPI), Hoescht dye 33258, and a monoclonal antibody against β-
tubulin were from Sigma Aldrich Co. LLC (St Louis, MO). The polyclonal antibody 
for active caspase-3 was from Promega (Madison, WI). Cy3- and FITC-conjugated 
secondary antibodies were from Jackson Immunoresearch Laboratories (West Grove, 
PA).  HPLC-grade methanol, acetonitrile, and ethyl acetate were obtained from Fisher 
Scientific (Pittsburg, PA). 
2.2. Cell culture, transfection, and treatment 
Rat cerebellar granule neurons (CGNs) were isolated as previously described 
from 7-day-old Sprague-Dawley rat pups of both sexes [130]. CGNs were seeded on 
35-mm diameter plastic dishes coated with poly-L-lysine at an average density of 2.0 
x 10
6
 cells/mL in basal modified Eagle’s medium containing 10% fetal bovine serum, 
25 mM KCl, 2 mM L-glutamine, and penicillin (100 units/mL)/streptomycin 
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(100µg/mL). Cytosine arabinoside (10 µM) was added to the culture medium 24h 
after plating. Experiments were performed after 6 days in culture. Immunocal® (3.3% 
w/v) was added in serum-free medium for 24h before treatment with the specified cell 
insult (i.e., SNP, HA14-1, etc.) for a further 24h. NSC34 motor neuron-like cells were 
seeded in a 6-well plate at an approximate density of 1.0 x 10
6
 cells/mL and 
maintained in DMEM high glucose medium containing 10% fetal bovine serum, 2 
mM L-glutamine, and penicillin (100 units/mL)/ streptomycin (100µg/mL).  For 
serum withdrawal, NSC34s were maintained in DMEM high glucose medium 
containing 1% fetal bovine serum, 2 mM L-glutamine, and penicillin (100 units/mL)/ 
streptomycin (100µg/mL) for 7 days prior to being seeded in a 6-well plate at an 
approximate density of 1.0 x 10
6
 cells/mL and subsequent experimental treatment.  
Immunocal® (3.3, 1.6, 1.1 % w/v) was added in culture medium for 24h before 
treatment with the specified cell insult (i.e. H2O2, glutamate glycine) in NSC34s. For 
transient transfection, CHO cells were seeded in a 6-well plate at an approximate 
density of 1.0 x 10
6
 cells/mL and then cultured for 24 hours in Ham’s F12 medium 
containing 10% fetal bovine serum, 2 mM L-glutamine, and penicillin (100 
units/mL)/ streptomycin (100µg/mL). Lipofection (5 μg DNA, 5 μL lipofectamine) 
was performed in serum-free medium for 6h to express vectors encoding DsRed-
tagged wild type APP or DsRed. Cells were incubated for 24h post-transfection in 
either the absence or presence of Immunocal®. 
 
 
28 
 
2.3. Cell viability, lipid peroxidation, and cellular GSH assay  
All assays were performed according to commercially available kit instructions. 
GSH/GSSG assay kit was purchased from Oxford Biomedical Research (Oxford, 
MI). MTT cell viability assay was from BioAssay Systems (Hayward, CA). 
Malondialdehyde (MDA) lipid peroxidation assay was obtained from OXIS Research 
Inc. (Foster City, CA). 
2.4. Immunocytochemistry 
After treatment, CGNs were fixed in 4% paraformaldehyde for 1h, washed once 
in PBS, and then permeabilized and blocked in 0.2% Triton X-100 and 5% BSA. 
Primary antibodies were diluted in 2% BSA and 0.2% Triton X-100 in PBS, and cells 
were incubated with primary antibodies for 24h at 4 
o
C. They were then washed 5 
times in PBS and then incubated for 1h with either Cy3- or FITC-conjugated 
secondary antibody diluted in 2% BSA and 0.2% Triton with DAPI. The cells were 
washed 5 times with PBS before the addition of anti-quench solution (0.1% p-
phenylenediamine in PBS). Images were captured using a Zeiss Axiovect-200 
incerted fluorescence microscope (Stuttgart, Germany). 
2.5. Animal model of ALS 
FVB-Tg(hSOD1-G93A) mice with the toxic gain of function hSOD1 Gly93 to 
Ala mutation (G93A) were obtained from The Jackson Laboratory (Bar Harbor, ME). 
The colony was maintained and bred in the animal facility at the University of 
Denver. Animal genotyping was done by the third party company, Transnetyx 
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(Cordova, TN). Animals of both sexes were included in each group, with an age and 
sex-matched non-transgenic FVB (NonTG) mouse as control. Animals receiving 
supplementation had ad libitum access to Immunocal® (3.3%) in drinking water 
beginning at 60 days old. Animals receiving SAE were administered a 5% solution 
via oral gavage twice daily. 
2.6. Clinical tests  
PaGE (paw grip endurance) test was determined by the latency of the animal’s 
hind limbs to detatch from a conventional housing wire cage lid after inversion, and 
was recorded as the average of 3 separate attempts. PaGE test was carried out twice 
weekly [131]. Animals were weighed every other day starting on day 30. End-stage 
was determined by a failure of the animal to right itself to sternum in 20s. Onset was 
determined by the appearance of trembling in one or two hind limbs or failure to 
extend one hind limb when suspended by the tail. All animal experiments were 
performed according to the University of Denver and IACUC approved protocol. 
2.7. Tissue processing 
Lumbar spinal cord and whole trunk blood were obtained from end-stage 
hSOD1
G93A
 or age and sex-matched NonTG mice following isoflurane overdose, and 
were immediately frozen in liquid nitrogen (-196 
o
C). For HPLC-EC analysis, trunk 
blood was weighed and 300 µL of HCl was added to the sample and vortexed rapidly. 
It was next centrifuged at 10,000 g for 20 minutes at 4 
o
C. The supernatant was 
removed and added to a new tube containing 10% perchloric acid (PCA), which was 
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centrifuged for 10 minutes at 10,000 g at 4 
o
C. A clear supernatant was removed and 
filtered. Lumbar spinal cord was weighed and added to 1 mL of 10% PCA and then 
vortexed 3 times for 15s each time. The supernatant was removed and filtered. Spinal 
cord GSH and GSSG were normalized to protein concentrations which were 
determined by a commercially available protein assay kit (BCA, Thermo Scientific, 
PA). Samples were analyzed in triplicate and an additional sample was spiked with 
GSH and GSSG to verify peak identification.  
2.8. High Performance Liquid Chromatography with Electrochemical Detection 
(HPLC-ECD) 
GSH and GSSG in samples and known standards were separated by reversed-
phase HPLC on a C18 bonded silica column at 35 
o
C (3µm, 3 x 150 mm for whole 
blood; 3µm, 3 x 250 mm for lumbar spinal cord) from Dionex, Inc. (Sunnyvale, CA). 
Analytes were detected using a CoulArray® detector (model 5600A, ESA) on three 
coulometric array cells in series; electrochemical detectors were set between 0 and 
900 mV at increments of 100 mV. Concentrations were determined with a standard 
curve of each identified analyte. Mobile phase consisted of 125 mmol/L Na3PO4 and 
1% methanol in water, pH 2.8 [132]. The flow rate was set to 0.4 mL/min for all 
samples. CoulArray® software was used for baseline correction and peak analysis.  
2.9. Anthocyanin purification and isolation 
Freeze dried strawberry powder was homogenized with methanol and HCl 
(0.01%) for 1h at 4 °C. The slurry was then filtered through Whatman no. 1 filter 
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paper under vacuum filtration at 40 °C. The filtrate was then applied to a Waters® 
C18 cartridge, rinsed with water and HCl (0.1%), and ethyl acetate. The final fraction 
left on the column was eluted using methanol and HCl (0.01%), and this final fraction 
was evaporated at 40 °C and re-suspended in water [133]. To confirm the purity of 
the final strawberry anthocyanin fraction, a sample was run on HPLC-UV with an 
Agilent model HP1100 series II with multi-wavelength detector (MWD) set to 520 
nm (Avondale, PA), using a reversed phase C18 bonded silica column (3µm, 3 x 150 
mm) from Dionex, Inc. (Sunnyvale, CA). 100 μL samples were injected and run at a 
flow rate of 0.6 mL/min, and the mobile phase consisted of 0.1% TFA in water and 
acetonitrile that were mixed as a gradient. The sample was compared to known 
anthocyanin standards.  
 
32 
 
 
Figure 5. Summary of anthocyanin purification process. 
 
2.10. Statistical analysis 
Each in vitro experiment was performed in duplicate and repeated a minimum of 
three times; data are reported as mean ± standard error of the mean. Statistical 
significance was analyzed with a one-way analysis of variance (ANOVA) followed 
by post hoc Tukey’s test. Survival and onset data were analyzed with Kaplan-Meier 
curves and log rank test with an n value of 13 for each treatment group.  
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Chapter 3: Results 
3.1. Immunocal® preserves cellular GSH and decreases apoptosis in CGNs exposed 
to the Bcl-2 inhibitor, HA14-1 
 
Figure 6. Immunocal® preserves cellular GSH and reduces apoptosis in CGNs exposed to the 
Bcl-2 inhibitor, HA14-1 A. Representative images of CGNs left untreated (control), treated with 
HA14-1 (15 μM), or pre-incubated for 24h with Immunocal® before HA14-1 treatment for a 
further 24h. Panels from left to right, pseudocolored dapi, pseudocolored β-tubulin, merged 
images showing β-tubulin, (green) and DAPI, (blue). Scale bar, 10 μm. B. Quantification of 
apoptosis for 4 independent experiments performed as in A except some cultures were pre-
incubated with 200 μM BSO as well. Apoptotic cells were those with condensed or fragmented 
nuclei. Results are shown as mean +/- SEM, n=4. *** indicates p<.001 compared to control, ††† 
indicates p<.001 compared to HA14-1, ‡‡‡ indicates p<.001 compared to ICAL + HA14-1. C. 
CGNs were treated exactly as described in B. Total cellular GSH was measured as described in 
Materials and Methods. Data shown represent the percent of control cellular GSH concentration, 
mean +/- SEM, n=4. *** indicates p<.001 compared to control, † indicates p<.05 compared to 
HA14-1, and ‡‡ indicates p<.01 compared to ICAL + HA14-1. Significant differences were 
determined by one way ANOVA with a post hoc Tukey’s test. Abbreviations used: Con, control; 
ICAL, Immunocal®; BSO, Buthionine sulfoximine. 
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Primary CGNs were initially incubated with Immunocal® for 24h, followed by a 
24h exposure to the BH3 mimetic, HA14-1 (15μM) as we have previously reported 
[134-136]. HA14-1 induced marked nuclear condensation and microtubule disruption 
(Fig. 6A) indicative of apoptosis (Fig. 6B) while also causing significant depletion of 
GSH (Fig. 6C). Immunocal® significantly protected CGNs from apoptosis induced 
by HA14-1 and significantly preserved GSH levels. To confirm that the mechanism 
of protection was due at least in part, to enhanced GSH synthesis, CGNs were co-
treated with Immunocal® and the γ-glutamyl cysteine synthetase-inhibitor, 
buthionine sulfoximine (BSO), which prevents GSH synthesis [137]. Co-incubation 
with Immunocal® and BSO for 24h before HA14-1 treatment completely prevented 
any protective effect that Immunocal® alone displayed against HA14-1 (Fig. 6B). 
Moreover, the capacity of Immunocal® to preserve cellular GSH levels upon HA14-1 
exposure was eliminated by BSO co-treatment (Fig. 6C). These data indicate that 
Immunocal® protects CGNs from MOS induced by the inhibition of Bcl-2 via an 
enhanced de novo synthesis of GSH. 
3.2. Immunocal® protects CGNs from CuCl2-induced oxidative damage and 
decreases cellular lipid peroxidation 
To further investigate the neuroprotective potential of Immunocal® in 
primary neurons, we used copper chloride (CuCl2) as a model of MOS. Copper 
overload is associated with free radical-induced fragmentation of mitochondrial 
cardiolipin and reduction in mitochondrial dehydrogenase and electron transport 
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chain complex activities [138,139]. This transition metal is known to generate 
reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) in vitro, and 
has been reported in abnormally high concentrations in several neurodegenerative 
diseases [140-141]. In addition, a central role for copper in the motor neuron 
death underlying ALS has been suggested [142].  
 
Figure 7. Immunocal® decreases CuCl2-induced apoptosis and lipid peroxidation in 
CGNs A. Representative images of CGNs left untreated (control), treated with CuCl2 (50 μM), or 
pre-incubated with Immunocal® for 24h before CuCl2 treatment for a further 24h. 
Immunocytochemistry shows β-tubulin (green), and DAPI (blue). Scale bar, 10 μm. B.  
Quantification of apoptosis for 4 independent experiments performed as in A. Results are shown 
as mean +/- SEM, n=4. ** indicates p<.01 compared to control, †† indicates p<.01 compared to 
CuCl2. C. Cellular lipid peroxidation (malondialdehyde, MDA) was measured as described in 
Materials and Methods.  Results are shown as mean +/- SEM, n=5.  ** indicates p<.01 compared 
to control, ††† indicates p<.001 compared to CuCl2. Abbreviations used: Con, control; ICAL, 
Immunocal®. 
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Fluorescence analysis of the microtubule network revealed robust protection from 
this transition metal in CGNs pre-treated with Immunocal® (Fig. 7A). Quantification 
of apoptotic cells revealed that there was a significant reduction in CGN apoptosis 
with Immunocal® pre-treatment compared to CGNs treated with CuCl2 alone (Fig. 
7B). The antioxidant effect of Immunocal® was confirmed with a lipid peroxidation 
assay which revealed a significant decrease in malondialdehyde content in CGNs pre-
treated with Immunocal® (Fig. 7C). 
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3.3. Immunocal® protects CGNs exposed to SNP-generated nitric oxide species and 
from AlCl3-induced neurotoxicity 
 
Figure 8. Immunocal® preserves CGN viability and protects from apoptosis after 
treatment with SNP A. Representative images of CGNs left untreated (control), treated with 
SNP (100 μM), or pre-incubated with Immunocal® for 24h before SNP treatment for a further 
24h. Immunocytochemistry shows β-tubulin (green), and DAPI (blue). Scale bar, 10 μm. B. 
Quantification of apoptosis for 5 independent experiments performed as in A. Results are shown 
as mean +/- SEM, n=5. C. MTT cell viability was measured as described in Materials and 
Methods. Results are shown as mean +/- SEM, n=3.For B and C, *** indicates p<.001 compared 
to control, ††† indicates p<.001 compared to SNP. Abbreviations used: Con, control; ICAL, 
Immunocal®. 
SNP is a nitric oxide donor that causes dissipation of the mitochondrial membrane 
potential and enhanced generation of mitochondrial ROS in cortical neurons and 
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CGNs [143-144]. As expected, nitric oxide species generated by SNP caused overt 
apoptotic cell death in CGNs which was significantly mitigated by pre-treatment with 
Immunocal® (Fig. 8A). Apoptotic cell counts confirmed that there was significant 
neuroprotection in CGNs pre-treated with Immunocal®, decreasing cell apoptosis by 
approximately 80% (Fig. 8B).  An MTT cell viability assay demonstrated similar 
results and showed that mitochondrial viability was also significantly preserved in 
Immunocal®-pre-treated cells, compared to CGNs treated with SNP alone (Fig. 8C). 
 
Figure 9. Immunocal® protects CGNs from AlCl3-induced toxicity A. Representative images of 
CGNs left untreated (control), treated with AlCl3 (10 μM), or pre-incubated with Immunocal® for 
24h before AlCl3 treatment for a further 48h. Panels from left to right, pseudocolored DAPI, 
pseudocolored β-tubulin, merged image showing β-tubulin (green), and DAPI (blue). Scale bar, 
10 μm. B. Cell survival was quantified for 4 independent experiments as described in A. Results 
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are shown as mean +/- SEM, n=4. *** indicates p<.001 compared to control, † indicates p<.05 
compared to AlCl3. Abbreviations used: Con, control; ICAL, Immunocal®. 
 
Aluminum is a neurotoxic metal that impairs mitochondrial structure and 
function in neural cells exposed in vitro and in vivo [145,146]. AlCl3-induced 
toxicity in CGNs was characterized by nuclear condensation and marked 
disruption of the microtubule network; these effects were markedly decreased in 
CGNs pre-treated with Immunocal® (Fig. 9A). To confirm that this protection 
was due to cysteine supplementation, and not metal chelation, we removed the 
Immunocal® after the pre-treatment period and washed the CGNs with serum-
free media before treating with AlCl3. Under these conditions, we still observed a 
significant increase in cell survival compared to CGNs treated with AlCl3 alone 
(Fig. 9B). 
3.4. Immunocal® prevents caspase-3 cleavage in CHO cells transfected with WT  
APP 
To explore the role of Immunocal® in a different cell model, we 
transiently transfected CHO cells with wild type (WT) APP. We have recently 
shown that overexpression of WT APP induces GSH-sensitive opening of the 
mitochondrial permeability transition pore and intrinsic apoptosis in CHO cells 
[13]. Both control cells transfected with an empty DsRed plasmid, as well as 
CHO cells overexpressing DSRed-WT APP that were incubated with 
Immunocal® post-transfection, expressed very low levels (10-20%) of active 
caspase-3. In contrast, untreated cells overexpressing WT APP showed a marked 
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increase in immunoactivity for active caspase-3 to approximately 50% (Fig. 10A). 
Quantification of active caspase-3 revealed that there was a significant decrease in 
CHO cell apoptosis in Immunocal®-treated cells compared to non-treated CHO 
cells overexpressing WT APP (Fig. 10B). 
 
Figure 10. Caspase-3 activation induced by wild type APP overexpression in CHO cells is 
decreased with Immunocal® treatment A. Representative images of CHO cells subject to wild 
type DsRed-APP overexpression in the absence or presence of Immunocal® incubation. Panels 
from left to right, pseudocolored DAPI, active caspase-3 (green), merged image showing active 
caspase-3 (green), and DsRed (red). Scale bar, 10 μm. B. Quantification of transfected CHO cells 
expressing active caspase-3. Results are shown as mean +/- SEM, n=4. *** indicates p<.001 
compared to DsRed, † indicates p<.05 compared to APP. Abbreviations used: APP, amyloid 
precursor protein; ICAL, Immunocal®. 
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3.5. Immunocal® protects NSC34 motor neuron-like cells from H2O2 and glutamate glycine-
induced toxicity 
Glutamate excitotoxicity is thought to play a role in ALS, leading to 
neuronal damage and apoptosis. NSC34 motor neuron-like cells are used as a 
model for studying motor neuron disease; however, cells do not express 
functional glutamate receptors until cells are exposed to serum withdrawal for 7 
days in culture and allowed to reach a higher level of maturity under these 
conditions rather than normal growing conditions. After this point cells become 
sensitive to glutamate excitotoxicity, which is an interesting in vitro model for 
ALS [147]. We show here that glutamate glycine (1 mM/100 μM) caused 
apoptotic cell death in NSC34s after serum withdrawal, which was significantly 
mitigated by pre-treatment with Immunocal®. An MTT cell viability assay 
demonstrated that mitochondrial viability was preserved in Immunocal®-pre-
treated cells in a dose-dependent manner, compared to NSC34 cells treated with 
glutamate glycine alone (Fig. 11A). 
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Figure 11. Immunocal® protects NSC34 cells from glutamate glycine and H2O2-induced toxicity 
A. Cell survival was quantified for 2 independent experiments in NSC34 left untreated (con), 
treated with glutamate glycine (1mM/100 μM), or pre-incubated with Immunocal® for 24h 
before glutamate glycine treatment for a further 24h. B. Cell survival was quantified for 2 
independent experiments in NSC34 left untreated (con), treated with H2O2 (250 μM), or pre-
incubated with Immunocal® for 24h before H2O2 treatment for a further 24h. Results are shown 
as mean +/- SEM, n=2. Abbreviations used: Con, control; ICAL, Immunocal®; glu. gly., 
glutamate glycine. 
 
H2O2-mediated cell apoptosis is a classic model of ROS in neuronal 
systems, as it generates free radicals that are hallmark in neurodegeneration [148]. 
As expected, ROS generated by H2O2 caused overt apoptotic cell death in 
NSC34s which was significantly mitigated by pre-treatment with Immunocal®. 
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An MTT cell viability assay demonstrated that mitochondrial viability was 
preserved in Immunocal®-pre-treated cells in a dose-dependent manner, 
compared to NSC34 cells treated with H2O2 alone (Fig. 11B).  
3.6. Immunocal® delays disease onset but does not extend lifespan in the hSOD1
G93A 
mouse model of ALS  
After finding that Immunocal® provided significant neuroprotection in vitro from 
multiple insults, we investigated the effects of Immunocal® supplementation in the 
hSOD1
G93A 
mouse model of ALS. Beginning at 60 days-of-age, mice received 
Immunocal® ad libitum in drinking water. Although there was no measurable 
difference in lifespan (Fig. 12A), Immunocal®-supplemented mice displayed a 
significant delay in disease onset of approximately 7 days (7 ±1.1 days) (Fig. 12B).  
Mice were visually assessed for deficits in motor function and coordination daily, 
and by PaGE hanging wire grip test twice a week. PaGE testing revealed a highly 
significant decrease in the rate of decline in grip strength between 100 days and 120 
days of age when Immunocal®-treated mice were compared to hSOD1
G93A 
mice that 
did not receive supplementation (Fig. 12C). Thus, Immunocal® preserved grip 
strength and delayed onset of motor dysfunction in this mouse model of familial ALS. 
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Figure 12. Immunocal® delays clinical onset and diminishes the rate of decline in grip 
strength in the hSOD1
G93A
 mouse model of ALS A. Median survival is not significantly 
different between hSOD1
G93A
 mice receiving Immunocal® ad libitum and untreated mutant mice 
(n= 13). B. hSOD1
G93A
 mice receiving Immunocal® ad libitum displayed a delay in disease onset 
and clinical decline compared to untreated mutant mice (n=13). Onset curves are significantly 
different (p<.001) determined  by  Gehan-Breslow-Wilcoxon Test. C. PaGE hanging wire test 
represented as (mean ± SEM) latency to fall at indicated ages (n=13). *** indicates p<.001 
compared to NonTG, ** indicates p<.01 compared to NonTG, † indicates p<.05 compared to 
hSOD1
G93A
 mice (one-way ANOVA with a post-hoc Tukey’s test). 
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3.7. Immunocal® prevents GSH depletion in whole blood and lumbar spinal cord of 
hSOD1
G93A 
mice 
 
Figure 13. HPLC-EC detection reveals whole blood GSH is depleted in the hSOD1
G93A
 mouse 
model of ALS and is preserved at NonTG levels in hSOD1
G93A
  mice receiving Immunocal® A. 
Mean GSH and GSSG concentrations and GSH/GSSG ratios from the whole blood of end stage 
trial animals, n=13. ** indicates p<.01, * indicates p<.05. B. Representative HPLC-EC 
chromatograms from the whole blood of end stage animals, peaks of interest include GSH 
oxidizing at 600 and 800 mV. 
 
The neuroprotective effects of Immunocal® observed in vitro are largely due to 
its capacity to enhance GSH synthesis by providing the key precursors cystine and 
cysteine. To investigate this potential mechanism of action in vivo, whole blood and 
lumbar spinal cord tissue was collected from end-stage hSOD1
G93A 
mice and analyzed 
for reduced GSH and oxidized GSSG using HPLC-ECD. We found that hSOD1
G93A 
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mice that did not receive supplementation displayed a significant decrease in whole 
blood GSH when compared to nontransgenic littermate controls (NonTG). Levels of 
GSSG in whole blood did not significantly change; however, the ratio of GSH to 
GSSG in whole blood was significantly decreased in hSOD1
G93A 
mice compared to 
NonTG controls. Both the decreases in GSH and the reduction in the GSH/GSSG 
ratio were prevented in hSOD1
G93A 
mice receiving Immunocal® (Fig. 13A). 
Representative HPLC chromatograms from these animals are shown in Figure 13B.  
Most interestingly, we found that a similar pattern also existed for GSH levels in 
the lumbar spinal cord of study animals. Spinal cord GSH levels were decreased by 
approximately 50%, GSSG levels were elevated two-fold, and the ratio of GSH to 
GSSG was significantly decreased in hSOD1
G93A 
mice compared to NonTG controls. 
Immunocal® treatment prevented these changes in GSH and GSSG and maintained 
the GSH/GSSG ratio at a level that was indistinguishable from NonTG controls (Fig. 
14A). These results indicate that preservation of whole blood and spinal cord GSH 
levels correlates with the beneficial effects of Immunocal® supplementation in the 
mutant hSOD1
G93A 
mouse model of ALS. Representative chromatograms from these 
animals are displayed in Figure 14B.  
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Figure 14. HPLC-EC detection reveals lumbar spinal cord GSH is depleted in the hSOD1
G93A
 
mouse model of ALS and is maintained at NonTG levels in hSOD1
G93A
  mice receiving 
Immunocal® A. Mean GSH and GSSG concentrations and GSH/GSSG ratios from the lumbar 
spinal cord of end stage trial animals n=17. * indicates p<.05. B.  Representative HPLC-EC 
chromatograms from the lumbar spinal cord of end stage animals, peaks of interest include GSH 
and GSSG oxidizing at 600 mV. 
 
3.8. Strawberry anthocyanin extract delays disease onset and extends lifespan in the 
hSOD1
G93A 
mouse model of ALS  
In addition to our studies with Immunocal®, we investigated a strawberry 
anthocyanin extract (SAE) for its efficacy in the SOD1
G93A
 mouse. After isolating the 
extract, we confirmed that the major anthocyanin in the final isolate was callistephin 
at 9.3 min retention time using HPLC-UV analysis (Fig.15). We next began oral 
dosing with a 5% solution of SAE twice daily in the hSOD1
G93A
 mouse model of 
ALS.  
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Figure 15. HPLC-UV identification of major anthocyanin in strawberry extract. A. 
Chromatogram of callistephin (Pelargonidin-3-O-glucoside) standard. B. Chromatogram of 
strawberry anthocyanin extract. 
 
We saw a significant delay in disease onset, and a significant increase in 
survival in the hSOD1
G93A
 mice receiving SAE (Fig. 16A&B). Additionally, there 
was a significant retention in motor function in the hSOD1
G93A
 mice receiving 
SAE (Fig. 16C). The antioxidant properties of these nutraceuticals, particularly at 
the level of the mitochondria, appear to underlie their neuroprotective effects; 
however, further investigation into the mechanism behind this neuroprotection is 
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necessary in further exploration of these compounds as natural therapies for 
neurodegenerative disease. 
 
Figure 16. SAE delays clinical onset, increases survival, and diminishes the rate of decline 
in grip strength in the hSOD1
G93A
 mouse model of ALS A. Median survival is different 
between hSOD1
G93A
 mice receiving Immunocal® ad libitum and untreated mutant mice (n= 2). B. 
hSOD1
G93A
 mice receiving Immunocal® ad libitum displayed a delay in disease onset and clinical 
decline compared to untreated mutant mice (n=2). C. PaGE hanging wire test represented as 
(mean ± SEM) latency to fall at indicated ages (n=2). *** indicates p<.001 compared to NonTG, 
** indicates p<.01 compared to NonTG, † indicates p<.05 compared to hSOD1G93A mice, †† 
indicates p<.01 compared to hSOD1
G93A
 mice, ††† indicates p<.001 compared to hSOD1G93A 
mice (one-way ANOVA with a post-hoc Tukey’s test). 
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Chapter 4. Discussion 
Here, we show that Immunocal® elevates cellular GSH levels and 
provides neuroprotection in vitro. We also show that it delays disease onset, 
attenuates decline in motor function, and sustains whole blood and spinal cord 
GSH at NonTG levels in the hSOD1
G93A 
mouse model of ALS. However, 
previous research using nutraceutical antioxidants in neurodegenerative disease 
has translated to relatively nominal clinical efficacy. For instance, vitamin E 
initially received a great deal of attention for its antioxidant activity in cellular 
and murine models of ALS, however its clinical translation was discouraging 
[149]. Yet there is a great deal of research that points to good nutrition and 
nutritional supplements as being clinically beneficial against neurodegeneration, 
arguing that there is promise within this field[150]. Nevertheless, there should be 
a greater selectivity of the nutritional supplements that make it to the clinic.  
Studies that point to a readily available and non-prescription relief for a 
disease as devastating as ALS may be an appealing alternative for affected 
patients. For this reason, among others, we looked to a nutraceutical antioxidant 
for its neuroprotective activity in these disease models. Immunocal® was a 
unique option because of its undenatured conformation and high cystine 
concentration, as well as its potential to mitigate some aspects of ALS that are 
hallmark in the disease [55]. It has been shown that ALS patients who receive 
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whey protein supplement present weight gain and increased body mass compared 
to control group patients, suggesting that Immunocal® may have this benefit in 
addition to its effects on the available GSH pool [151].  
Although researchers may disagree on the correct path to potential 
therapeutics, there is an understanding in the field that neurodegenerative 
diseases, such as ALS, have underlying mitochondrial dysfunction. Therefore, 
there is an emerging class of treatment modalities that target mitochondrial 
function as a potential therapy. For instance, dexpramipexole, a drug that is 
currently in phase III clinical trials for ALS is a mitochondrial modulator, and has 
had encouraging results in phase I and II trials. It is suspected to preserve 
mitochondrial function through its antioxidant activity, inhibition of pro-apoptotic 
proteins, and preserving mitochondrial structure [152, 153]. Effective treatments 
that target mitochondrial function such as dexpramipexole suggest that 
mitochondrial dysfunction is an underlying aspect of ALS, and therapies that 
target mitochondrial antioxidant defenses similarly hold promise in this field. 
Mitochondrial GSH depletion is associated with increased apoptosis in 
NSC34 cells stably expressing the hSOD1
G93A
 mutation [51]. Additionally, GSH 
depletion in the hSOD1
G93A
 mouse is correlated with increased age-dependent 
motor degeneration [154]. Therefore, increasing the available cellular and 
mitochondrial GSH pool, and decreasing oxidative stress by promoting 
endogenous cellular defenses is an appealing treatment modality. As 
aforementioned, cysteine supplementation and providing the limiting precursor 
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for GSH synthesis holds promise for therapy in various neurodegenerative 
diseases, including ALS [155]. In accordance with these data, Immunocal® 
treatment and modulation of the GSH pool is a very promising therapy for ALS, 
particularly at the level of the mitochondria.  
It is posited that the best exogenous precursor for GSH is the amino acid 
cystine [156]. Cystine is transported across the astroglial cell membrane in 
exchange for glutamate by the X
-
c transport system in astroglial cells, and it is 
broken down into cysteine and used in GSH biosynthesis [157]. Although this is 
not the only mechanism behind the anti-apoptotic role of Immunocal®, this is an 
interesting aspect of the supplement and further investigation is necessary into 
this potential neuroprotective role. 
In this study, we also showed that strawberry anthocyanins provided 
neuroprotection in the hSOD1
G93A
 mice. These preliminary data are very 
promising and suggest that there may indeed be a role for these nutraceuticals in 
the clinic after further investigation into their mechanism of action. In addition to 
our findings, several recent in vivo studies have exhibited exciting results using 
anthocyanins, suggesting that these novel nutraceuticals could be beneficial in a 
clinical setting for neurodegenerative diseases. A central aim of these other 
studies was to examine the therapeutic potential of anthocyanins in the treatment 
of specific neurodegenerative diseases, specifically using animal models of PD. In 
the MPTP mouse, a neurotoxin model widely used to test potential therapeutic 
options for PD, anthocyanin treatment preserved dopamine neurons in the 
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substantia nigra pars compacta and dopaminergic innervation of the striatum 
[114]. Anthocyanins have also exhibited neuroprotection in rats subjected to 
unilateral striatal lesioning with 6-OHDA, reinforcing their potential in this 
particular neurodegenerative disease [158]. Anthocyanins have also been shown 
to have neuroprotective effects in in vivo models of acute neuronal injury such as 
middle cerebral artery occlusion and reperfusion in rats [159]. 
Anthocyanins have also been examined in models of aging, as research 
suggests that oxidative stress plays a large role in the etiology of aging. Recent 
studies investigating anthocyanins have revealed other potential benefits of these 
nutraceuticals. Anthocyanins appear to diminish age-related oxidative stress 
[106,160]. Treatment with anthocyanins significantly attenuated cytosolic 
cytochrome c release, and promoted neuronal survival in a model of D-galactose-
induced brain aging in old mice [106]. Finally, in a recent clinical study, 
consumption of wild blueberry juice for 12 weeks enhanced memory performance 
in older adults with early symptoms of dementia [160]. These data are suggestive 
of a possible therapeutic role for anthocyanins in age-associated cognitive 
impairment. 
An important element of anthocyanin treatment is the cell type-specific 
effects of these compounds exhibited both in vitro and in vivo. As they act in a 
pro-apoptotic fashion in cancer cells, and as anti-apoptotic agents in neurons, it is 
clear that their effects on cell physiology are complex.  
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Anthocyanins affect many different signaling pathways in different cell 
systems. They exhibit anti-proliferative, anti-inflammatory, and pro-apoptotic 
effects in cancer cells, supportive of their use as chemotherapeutic agents. They 
also exhibit strong antioxidant and anti-apoptotic effects in neuronal injury 
models, which provides evidence toward the potential of anthocyanins as a novel 
treatment for neurodegeneration. In vivo studies in animal models of 
neurodegeneration involving anthocyanins have delivered promising results that 
may lean towards their clinical development in neurodegenerative diseases. 
Studies in human subjects are limited, but are also promising for this treatment 
modality. These novel nutraceuticals displayed promising effects in preliminary 
clinical studies of memory impairment in older adults, again suggesting the 
potential benefit of developing anthocyanins for the treatment of 
neurodegenerative diseases [160]. Though the data in human models are limited 
and preliminary, they provide a basis for more comprehensive human trials of 
anthocyanins as neuroprotective agents. Seeing the clinical potential of 
anthocyanins, recent studies are directed towards delivery methods of these 
anthocyanins in vivo, even looking toward slow anthocyanin-releasing implants 
for a novel delivery method in disease prevention and treatment.  
The unique properties of anthocyanins may be extremely beneficial for the 
clinical treatment of chronic human diseases, as diverse as cancer and 
neurodegeneration. Future development of these nutraceuticals as neuroprotective 
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agents will one day hopefully lead to their use in a clinical setting for the 
treatment of neurodegenerative diseases as well as highly invasive cancers. 
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Chapter 5: Conclusions and future directions 
 Experiments in vitro have convincingly demonstrated that cystine 
supplementation via Immunocal® may be promising against an array of 
neurodegenerative disease-relevant insults. Here, we show that Immunocal® 
protects CGNs against the Bcl-2 inhibitor, HA14-1, and that this effect is 
diminished when CGNs are co-incubated with BSO, which is a de novo GSH 
synthesis inhibitor. Futhermore, we show that Immunocal® protects CGNs from 
CuCl2 , AlCl3, and SNP-induced toxicity. In CHO cells that are transiently 
transfected with wild type APP, Immunocal® decreases active caspase-3 
expression. Moreover, in NSC34 motor neuron cells we saw that Imunocal® 
increased cell viability in a dose-dependent manner in cells treated with either 
H2O2 or glutamate glycine. These data are promising in vitro, and were 
encouraging enough to study the effects of Immunocal® in the hSOD1
G93A
 mouse 
model of ALS. We found that Immunocal® administered orally ad libitum 
reduced age-associated decline in muscle function, as measured by the PaGE grip 
endurance test. We also show that Immunocal® increased healthspan by delaying 
disease onset in mutant mice. Finally, we show that Immunocal® prevented 
whole blood and spinal cord GSH depletion in the hSOD1
G93A
 mice, and 
maintained GSH at NonTG levels in the mice receiving supplementation.  
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After isolating an anthocyanin-enriched fraction from freeze-dried 
strawberries (SAE) and testing their efficacy in the hSOD1
G93A
 mouse model of 
ALS, we show a significant neuroprotective effect. SAE significantly delayed 
disease onset and extended survival in the hSOD1
G93A
 mice receiving the extract 
orally. We also show a significant retention in motor function, as measured by the 
PaGE grip endurance test. These data are preliminary, and further investigation 
into the mechanism of action is necessary to further develop these compounds for 
their neuroprotective effects. These collective data suggest that nutraceutical 
intervention holds potential in neuroscience, and that compounds such as 
Immunocal® and SAE deserve further investigation in models of 
neurodegeneration. 
 
Figure 17. Schematic of possible clinical synergy leading to neuroprotection. 
 
Our future studies involving these compounds will model a clinical 
synergy approach to pharmacologically moderate cell death. For instance, if we 
combine Immunocal® with the glutamate inhibitor, Riluzole, we should see an 
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increase in survival in the hSOD1
G93A
 mouse, as these compounds will affect 
different aspects of neurodegeneration that are hallmark in these diseases (Fig. 
16.) Furthermore, if we couple these compounds with an Nrf2-inducer, which will 
increase GSH synthesis, we will theoretically see an increase in the resulting 
neuroprotection. Future studies with Immunocal® are promising and they should 
give rise to a novel approach using nutraceuticals to enhance pharmacological 
intervention in ALS and other neurodegenerative disorders. 
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